Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

计划入组 15 人 · 首次发布于 2024 年 12 月 12 日

ALPs Single ChambEr New Device

计划入组 10 人 · 首次发布于 2026 年 3 月 10 日

Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma

计划入组 77 人 · 首次发布于 2003 年 9 月 9 日

ALPS-12

FAS-115

FAS-3075

TAS

Université Grenoble Alpes

France

Cell2Cure ApS

Denmark

Pharming Group Initiates Phase II Trial of Leniolisib for Primary Immunodeficiencies

Corvus Pharmaceuticals Initiates Phase 2 Trial of Soquelitinib for Rare Genetic Disease ALPS

Alps Group Completes $1.6 Billion SPAC Merger, Lists on Nasdaq to Advance Precision Medicine Platform